Citigroup Maintains Buy on Guardant Health, Raises Price Target to $215

Guardant Health

Guardant Health

GH

0.00

Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ: GH) with a Buy and raises the price target from $150 to $215.